66%; HR, 0.76; 95% CI, 0.68–0.86;P< .0001), despite a crossover of 52% of the patients on observation.One year of trastuzumab also improved OS (12-year OS rate, 79% vs.
73%; HR, 0.74; 95% CI, 0.64–0.86;P< .0001).[129][Level of evidence A1]The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to 2 years of trastuzumab:After a median follow-up of 11 years, there was no DFS benefit to an additional year of trastuzumab (HR, 1.02; 95% CI, 0.89–1.17).Symptomatic cardiac events occurred in 1% of the patients who received trastuzumab and in 0.1% of the observation group.